Table 1.
Guix et al. [15] | Montero et al. [16] | Vavassori et al. [2] | Jain et al. [17] | Our study | |
---|---|---|---|---|---|
Number of patients | 16 | 2 | 7 | 1 | 1 |
Histology | BCC 16 | BCC 2 | BCC 5, SC 2 | SCC 1 | SC 1 |
Total dose | 60–66 Gy/33–36 fx | 44–48 Gy/11–12 fx | 30–48 Gy/10–17 fx | 40 Gy/10 fx | 52 Gy/13 fx |
Median follow-up (mo) | - | 15 (4–36) | 51 (16–90) | 40 | 6 |
Local control (%) | 100 | 100 | 100 | 100 | 100 |
Good cosmetic outcome (%) | 100 | - | 100 | 100 | 100 |
BCC, basal cell carcinoma; SCC, squamous cell carcinoma; SC, sebaceous carcinoma.